Novel peptide for attenuation of hypoxia-induced pulmonary hypertension via modulation of nitric oxide release and phosphodiesterase -5 activity

Peptides

Volumn 35, Issue 1, 2012, Pages 78-85

  Hu, Hanbo ^b   Zharikov, Sergey ^b   Patel, Jawaharlal M ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Cyclic GMP; Hypoxia; Nitric oxide; Phosphodiesterase 5; Pulmonary artery pressure; Pulmonary hypertension; Synthetic peptide; Telemetry

Indexed keywords

ACETYLCHOLINE; CYCLIC AMP; CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PHOSPHODIESTERASE V; SERYLSERYLTRYPTOPHANYLARGINYLARGINYLLYSYLARGINYLLYSYLGLUTAMINYLSERYLSERINE; SYNTHETIC PEPTIDE; TRITIUM; UNCLASSIFIED DRUG; ZAPRINAST;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; HEART RIGHT VENTRICLE HYPERTROPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; HYPOXIA; LUNG ARTERY PRESSURE; MALE; MASS SPECTROMETRY; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; SWINE; TELEMETRY; TISSUE CULTURE; VASOCONSTRICTION;

AMINO ACID SEQUENCE; ANIMALS; BLOOD PRESSURE; CELL HYPOXIA; CELLS, CULTURED; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; ENDOTHELIAL CELLS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; LUNG; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PEPTIDE FRAGMENTS; PHOSPHODIESTERASE 5 INHIBITORS; PROTEIN BINDING; PULMONARY ARTERY; RATS; RATS, SPRAGUE-DAWLEY; SWINE; VASODILATOR AGENTS;

RATTUS; SUS;

EID: 84859790393     PISSN: 01969781     EISSN: 18735169     Source Type: Journal    
DOI: 10.1016/j.peptides.2012.03.009     Document Type: Article

References (27)

1. Colbran JL, Francis SH, Leach AB, Thomas MK, Jiang H, McAllister LM, et al. A phenylalanine in peptide substrates provides for selectivity between cGMP- and cAMP-dependent protein kinases. J Biol Chem 1992;267:9589-94.
2. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991;115:343-9.
3. Davis MG, Fulton GJ, Hagen PO. Clinical biology of nitric oxide. Br J Surg 1995;82:1598-610.
4. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004;351:1655-65.
5. Feron O, Dessy C, Moniotte S, Desager JP, Balligand JL. Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase. J Clin Invest 1999;103:897-905. (Pubitemid 29152636)
6. Garcia-Cardena G, Fan R, Stern DF, Liu J, Sessa WC. Endothelial cell nitric oxide synthase is regulated by tyrosinee phosphorylation and interacts with caveolin-1. J Biol Chem 1996;271:27237-40. (Pubitemid 26367273)
7. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995;333:214-21.
8. Hess P, Clozel M, Clozel JP. Telemetry monitoring of pulmonary arterial pressure in freely moveing rats. J Appl Physiol 1996;81:1027-32. (Pubitemid 26303261)
9. Hu H, Xin M, Belayev LL, Zhang JL, Block ER, Patel JM. Autoinhibitory domain fragment of endothelial NOS enhances pulmonary artery vasorelaxation by the NO/cGMP pathway. Am J Physiol Lung Cell Mol Physiol 2004;286:L1066-74. (Pubitemid 38508818)
10. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-36.
11. Hutchinson TE, Kuchibhotla S, Block ER, Patel JM. Peptide-stimulation enhances compartmentalization and the catalytic activity of lung endothelial NOS. Cell Physiol Biochem 2009;24:471-82.
12. Hutchinson TE, Zhang J, Xia SL, Kuchibhotla S, Block ER, Patel JM. Enhanced phosphorylation of caveolar PKC-α limits peptide internalization in lung endothelial cells. Mol Cell Physiol 2012;360:309-20.
13. Li YD, Block ER, Patel JM. Activation of multiple signaling modules is critical in angiotensin IV-induced lung endothelial cell proliferation. Am J Physiol Lung Cell Mol Physiol 2002;283:L707-16.
14. Marletta MA. Nitric oxide synthase structure and mechanism. J Biol Chem 1993;268:12231-4. (Pubitemid 23182366)
15. McDonald LJ, Murad F. Nitric oxide and cyclic GMP signaling. Proc Soc Exp Biol Med 1996;211:1-6.
16. Rose RJ, Liu H, Palmer D, Maurice DH. Cyclic AMP-mediated regulation of vascular smooth muscle cell cyclic AMP phosphodieasterase activity. Br J Pharmacol 1997;122:233-40. (Pubitemid 27397193)
17. Rotella DP. Phosphodiesterase 5 inhibitors: current status and potential applications. Nat Rev Drug Discov 2002;1:674-82. (Pubitemid 37361542)
18. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997;336:111-7. (Pubitemid 27020889)
19. Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet 2003;361:1533-44. (Pubitemid 36566349)
20. Sastry BKS, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled study. J Am Coll Cardiol 2004;43:1149-53. (Pubitemid 38452588)
21. Stiebellechner L, Petkov V, Vonbank K, Funk G, Shenk P, Ziesche R, et al. Longterm treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. Chest 2003;123:1293-5. (Pubitemid 36444392)
22. Thompson WJ, Appleman MM. Multiple phosphodiresterase activities from rat brain. Biochemistry 1971;10:311-6.
23. Wilkens H, Guth A, Koing J, Forestier N, Cremers B, Hennen B, et al. Effects of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001;104:1218-22. (Pubitemid 32848108)
24. Wharton J, Strange JW, Moller GMO, Growcott EJ, Ren X, Franklyn AP, et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 2005;172:105-13. (Pubitemid 40923321)
25. Wilkens H, Guth A, Koing J, Forestier N, Cremers B, Hennen B, et al. Effects of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001;104:1218-22. (Pubitemid 32848108)
26. Wilkens MR, Paul GA, Strange JW, Tunariu N, Gin-Sing W, Banya WA, et al. Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study. Am J Respir Crit Care Med 2005;171:1292-7. (Pubitemid 40740738)
27. Zharikov SI, Krotova K, Hu H, Baylis C, Johnson RJ, Block ER, et al. Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells. Am J Physiol Cell Physiol 2008;295:C1183-90. (Pubitemid 352790338)